Related to Ticking Time Bomb: Resetting the Flu’s Clock

• Juvaris Rakes In $25M to Advance Adjuvant Development
  
• Optimer Reports Positive Phase III Data for Antibiotic against C. Difficile
  
• Immune Targeting System Adds £8.65M to Series A Funds to Take Universal Flu Vaccine through Phase II
  
• PPD and Southern Research Ally on Services for Influenza Research
  
• AiCuris Raises €55M to Continue Phase II Trials of Cytomegalovirus Drug Candidate
  
• GlycoVaxyn and Brigham and Women’s Win $3.4M to Develop S. aureus Vaccine
  
• Crucell Receives $110M UNICEF Contract for Quinvaxem Pediatric Vaccine
  
• GC-Rise and JS Bio Pharm Sign Separate Agreements for MediGene’s Genital Warts Treatment
  
• Synedgen Wins $2.73M U.S. Army Grant to Combat Drug-Resistant Bacteria
  
• MitoSciences Nabs $590K NIH Grant to Develop Companion Diagnostics for Antivirals
  
• Trius Wins $29.5M Contract to Develop Antibiotics for Gram-Negative Pathogens
  
• Investigators Identify Variants Linked to Risk of Developing Infectious Diseases
  
• Optimer Taps Biocon to Supply Commercial-Scale API for C. Difficile Treatment
  
• Virginia Commonwealth Uni to Evaluate Prophylactic CMV Vaccination Strategies with Vical
  
• Pevion to Use Cevec’s Protein-Expression Technology for Infectious Disease Vaccine
  
• Researchers Develop Approach in Mice to Treat Tularemia
  
• Tetraphase Pockets $45M to Progress Next-Generation Tetracyclines
  
• Cytheris Scores €12M Financing to Progress IL-7 Pipeline
  
• Sanofi Pasteur Pays Vivalis €3M for Access to Human mAb Platform for Infectious Diseases
  
• IncellDx to Start U.S. Clinical Trials of HPV Test with $3M Financing